share_log

AbbVie | 8-K: AbbVie Reports Third-Quarter 2024 Financial Results

AbbVie | 8-K: AbbVie Reports Third-Quarter 2024 Financial Results

艾伯維公司 | 8-K：艾伯維公佈2024年第三季度財務業績
美股SEC公告 ·  2024/10/30 19:47

Moomoo AI 已提取核心訊息

AbbVie reported Q3 2024 revenues of $14.46 billion, up 3.8% year-over-year, driven by strong performance across key portfolios. Immunology revenues grew 3.9% to $7.05 billion, with Skyrizi and Rinvoq showing robust growth of 50.8% and 45.3% respectively, offsetting Humira's 37.2% decline. Neuroscience revenues increased 15.6% to $2.36 billion, led by Vraylar and Botox Therapeutic.The company raised its full-year 2024 adjusted EPS guidance to $10.90-$10.94 from $10.67-$10.87, reflecting strong business momentum. Additionally, AbbVie announced a 5.8% increase in quarterly dividend to $1.64 per share, marking its 310% dividend growth since 2013.AbbVie completed the acquisition of Cerevel Therapeutics, strengthening its neuroscience portfolio with complementary pipeline assets. The company also reported positive Phase 3 results for tavapadon in early Parkinson's disease and received FDA approval for Vyalev as the first subcutaneous 24-hour levodopa-based therapy for advanced Parkinson's disease.
AbbVie reported Q3 2024 revenues of $14.46 billion, up 3.8% year-over-year, driven by strong performance across key portfolios. Immunology revenues grew 3.9% to $7.05 billion, with Skyrizi and Rinvoq showing robust growth of 50.8% and 45.3% respectively, offsetting Humira's 37.2% decline. Neuroscience revenues increased 15.6% to $2.36 billion, led by Vraylar and Botox Therapeutic.The company raised its full-year 2024 adjusted EPS guidance to $10.90-$10.94 from $10.67-$10.87, reflecting strong business momentum. Additionally, AbbVie announced a 5.8% increase in quarterly dividend to $1.64 per share, marking its 310% dividend growth since 2013.AbbVie completed the acquisition of Cerevel Therapeutics, strengthening its neuroscience portfolio with complementary pipeline assets. The company also reported positive Phase 3 results for tavapadon in early Parkinson's disease and received FDA approval for Vyalev as the first subcutaneous 24-hour levodopa-based therapy for advanced Parkinson's disease.
艾伯維公司報告2024年第三季度收入爲144.6億美元，同比增長3.8%，得益於核心產品組合的強勁表現。免疫學收入增長3.9%，達到70.5億美元，其中Skyrizi和Rinvoq分別顯示出50.8%和45.3%的強勁增長，抵消了Humira 37.2%的下降。神經科學收入增長15.6%，達到23.6億美元，由Vraylar和Botox治療推動。該公司將2024年全年調整後每股收益指引提高至10.90美元至10.94美元，低於之前的10.67美元至10.87美元，反映出強勁的業務勢頭。此外，艾伯維公司宣佈季度股息增加5.8%，達到每股1.64美元，自2013年以來增長310%。艾伯維公司完成了...展開全部
艾伯維公司報告2024年第三季度收入爲144.6億美元，同比增長3.8%，得益於核心產品組合的強勁表現。免疫學收入增長3.9%，達到70.5億美元，其中Skyrizi和Rinvoq分別顯示出50.8%和45.3%的強勁增長，抵消了Humira 37.2%的下降。神經科學收入增長15.6%，達到23.6億美元，由Vraylar和Botox治療推動。該公司將2024年全年調整後每股收益指引提高至10.90美元至10.94美元，低於之前的10.67美元至10.87美元，反映出強勁的業務勢頭。此外，艾伯維公司宣佈季度股息增加5.8%，達到每股1.64美元，自2013年以來增長310%。艾伯維公司完成了對Cerevel Therapeutics的收購，加強了其神經科學產品組合，擁有互補的管線資產。該公司還報告了tavapadon在早期帕金森病的三期臨牀試驗的積極結果，並獲得FDA批准，Vyalev成爲首個用於晚期帕金森病的24小時皮下給藥基於左旋多巴的治療。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Medicus Pharma
    MDCX
    -- 3.680
    Scilex Holding
    SCLX
    -- 0.354
    阿瑪琳
    AMRN
    -- 0.612
    賽諾菲安萬特
    SNY
    -- 54.500
    艾伯維公司
    ABBV
    -- 192.870
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！